 |
|
|
|
March 2002 Cover
|
|
British drug maker GlaxoSmithKline announced this month that it will begin a US clinical trial of a vaccine to prevent humans from being infected with HIV. Healthy males and females who
have not been exposed to the virus and who are at low risk of HIV infection will be enrolled through 11 clinical research centers in the United States.
The vaccine consists of two key proteins found on the virus, as well as an "adjuvant" substance meant to enhance the effectiveness of the vaccine. In pre-clinical trials, the
experimental vaccine protected rhesus monkeys from simian-human immunodeficiency virus (SHIV), a potent virus similar to HIV.
Editor's Note: from Reuters
You are not logged in.
No comments yet, but
click here to be the first to comment on this
HIV Digest!
|
|
|
|
|
